Skip to content
10-Q

Quarterly Report

Forte Biosciences, Inc. FBRX

0001193125-26-215862

← back to feed
Filed
May 11, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Capex Q1 2026 · Mar 31, 2026 $0
Capex Q1 2026 · Mar 31, 2025 $61K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$18.81M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$10.36M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $58.22M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $76.96M
Stockholders Equity Q1 2026 · Mar 31, 2026 $42.1M
Stockholders Equity Q1 2026 · Dec 31, 2025 $60.99M
Stockholders Equity Q1 2026 · Mar 31, 2025 $38.43M
Stockholders Equity Q1 2026 · Dec 31, 2024 $52.48M
Current Liabilities Q1 2026 · Mar 31, 2026 $23.65M
Current Liabilities Q1 2026 · Dec 31, 2025 $20.75M
Total Liabilities Q1 2026 · Mar 31, 2026 $25.12M
Total Liabilities Q1 2026 · Dec 31, 2025 $21.79M
Current Assets Q1 2026 · Mar 31, 2026 $65.11M
Current Assets Q1 2026 · Dec 31, 2025 $80.59M
Total Assets Q1 2026 · Mar 31, 2026 $67.22M
Total Assets Q1 2026 · Dec 31, 2025 $82.78M
Eps Diluted Q1 2026 · Mar 31, 2026 −$1.24
Eps Diluted Q1 2026 · Mar 31, 2025 −$1.37
Eps Basic Q1 2026 · Mar 31, 2026 −$1.24
Eps Basic Q1 2026 · Mar 31, 2025 −$1.37
Sga Expense Q1 2026 · Mar 31, 2026 $1.97M
Sga Expense Q1 2026 · Mar 31, 2025 $3.43M
Net Income Q1 2026 · Mar 31, 2026 −$22.14M
Net Income Q1 2026 · Mar 31, 2025 −$15.66M
Operating Income Q1 2026 · Mar 31, 2026 −$22.44M
Operating Income Q1 2026 · Mar 31, 2025 −$16.12M